Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
All content is framed for research use only no clinical or therapeutic claims are made
Key Features: Designed for agonist screening applications GLP1R, GIPR, GCGR target coverage Flexible setup for single and multi target evaluation To support efficient drug development in metabolic diseases, Genomeditech presents The Season of Metabolic Disease Targets, featuring preferential pricing on selected metabolic disease-related products, with up to 40% off
For instance, semaglutide treatment is now used both for diabetes management and as an obesity treatment
Here are a few examples: Europe : Ozempic has been approved by the European Medicines Agency (EMA) to treat type 2 diabetes
US$ 27.37
US$ 26.80
US$ 23.21
US$ 29.56
US$ 24.15
